The Swiss pharma giant plans to offload its generics unit on or around October 4, it said on Friday. Shareholders will receive one Sandoz share for every five Novartis shares held.
This content was published on
2 minutes
Reuters/sp
Português
pt
Novartis pretende realizar em outubro a cisão da unidade Sandoz
Novartis shareholders will vote on the details of the plan at an extraordinary general meeting (EGM) on September 15, a year after the Basel-based firm announced its plans to split Sandoz into a separate entity, ReutersExternal link and other media reported on Friday.
“If Novartis shareholders approve the proposed special distribution at the EGM, the spin-off will be implemented through the distribution of a dividend-in-kind of Sandoz shares to Novartis shareholders, and of Sandoz ADRs (American Depositary Receipts) to Novartis ADR holders,” the company said in a statement.
The Swiss drugmaker’s plan to separate out its generic drug unit Sandoz is aimed at focusing on the production of more lucrative patent medicines. In 2021, following mounting pricing pressures in the US off-patent medicines sector, Sandoz was put under a strategic review by Novartis CEO Vas Narasimhan.
The generics unit accounted for around 10% of Novartis’ core operating profit of $16.7 billion (CHF14.6 billion) in 2022 and the drug company is now planning to divest almost one-fifth of its business in terms of sales.
Should raw milk sales be banned or should consumers decide?
Swiss food regulations do not allow raw milk to be sold for direct consumption. However, a loophole allows 400 raw milk vending machines to do just that.
AI can reduce the number of animals needed for research
This content was published on
Swiss researchers have developed a new, AI-supported method that analyses the behaviour of mice in the laboratory more efficiently.
Geneva Conventions conference on Middle East scheduled for March 2025
This content was published on
The conference on the Middle East of the 196 States party to the Geneva Conventions, organised by Switzerland, will take place in Geneva in March.
Swiss university graduates are popular hires worldwide
This content was published on
Graduates of Swiss universities are popular with international employers, according to the Global Employability University Rankings.
French cross-border workers in Switzerland fear ‘discriminatory’ unemployment reform
This content was published on
In the French region around Geneva, cross-border workers are protesting proposals to cut unemployment benefits for those working in Switzerland.
Novartis seals deal to license high-priced cancer drug
This content was published on
Swiss pharma giant Novartis has finalised a deal to allow generic production of its patented drug nilotinib to treat chronic myeloid leukemia.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.